Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. He K, et al. Among authors: richards da. J Thorac Oncol. 2023 Jul;18(7):907-921. doi: 10.1016/j.jtho.2023.02.016. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36842467 Free PMC article. Clinical Trial.
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M, Dasse KD. Richards DA, et al. Ann Oncol. 2006 Jul;17(7):1096-102. doi: 10.1093/annonc/mdl081. Epub 2006 Apr 26. Ann Oncol. 2006. PMID: 16641168 Free article. Clinical Trial.
Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
Socinski MA, Raju RN, Neubauer M, Smith DA, Richards DA, Savin M, Ruxer RL, Reynolds CH, Zhan F, Bromund JL, Chen R, Obasaju C. Socinski MA, et al. Among authors: richards da. J Thorac Oncol. 2008 Nov;3(11):1308-16. doi: 10.1097/JTO.0b013e3181898e32. J Thorac Oncol. 2008. PMID: 18978567 Free article. Clinical Trial.
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. Kindler HL, et al. Among authors: richards da. Ann Oncol. 2012 Nov;23(11):2834-2842. doi: 10.1093/annonc/mds142. Epub 2012 Jun 13. Ann Oncol. 2012. PMID: 22700995 Free article. Clinical Trial.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. Patel JD, et al. Among authors: richards da. J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145346 Free PMC article. Clinical Trial.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Jotte RM, Von Hoff DD, Braiteh F, Becerra CR, Richards DA, Smith DA, Garbo L, Stephenson J, Conkling PR, Robert-Vizcarrondo F, Chen J, Turner PK, Chow KH, Tai DF, Ilaria R Jr. Jotte RM, et al. Among authors: richards da. Invest New Drugs. 2015 Feb;33(1):148-58. doi: 10.1007/s10637-014-0160-z. Epub 2014 Sep 28. Invest New Drugs. 2015. PMID: 25260842 Clinical Trial.
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR. Yu H, et al. J Thorac Oncol. 2017 Jan;12(1):110-120. doi: 10.1016/j.jtho.2016.09.002. Epub 2016 Sep 14. J Thorac Oncol. 2017. PMID: 27639678 Free PMC article.
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. Dickler MN, et al. Among authors: richards da. Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23. Clin Cancer Res. 2018. PMID: 29793946 Free PMC article. Clinical Trial.
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Murray Stewart T, Von Hoff D, Fitzgerald M, Marton LJ, Becerra CHR, Boyd TE, Conkling PR, Garbo LE, Jotte RM, Richards DA, Smith DA, Stephenson JJ Jr, Vogelzang NJ, Wu HH, Casero RA Jr. Murray Stewart T, et al. Among authors: richards da. Cancer Chemother Pharmacol. 2021 Jan;87(1):135-144. doi: 10.1007/s00280-020-04201-1. Epub 2020 Nov 19. Cancer Chemother Pharmacol. 2021. PMID: 33215270 Free PMC article. Clinical Trial.
409 results